MedTrace Logo

Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy

NCT01068470 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2014-05-29

No results posted yet for this study

Summary

Therapy with Interleukin-2 stimulates lymphocytes in humans to become Lymphokine-activated Killer cells (LAK). This study will determine if these killer cells are able to kill certain standard cell-lines in the laboratory.

Conditions

Sponsors & Collaborators

  • Loma Linda University

    lead OTHER

Principal Investigators

  • Walter Quan, MD · Loma Linda University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-12-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01068470 on ClinicalTrials.gov